Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is FAST-Forward/ultra-hypofractionation suitable for an early-stage breast patient after a lumpectomy with oncoplastic reduction?
Answer from: Radiation Oncologist at Community Practice
Yes, FAST-Forward is fine after oncoplastic reduction as long as dose homogeneity criteria can be met (V105 < 5%).
Sign in or Register to read more
26566
Related Questions
In a patient with cardiac comorbidities, who meets ASTRO APBI criteria other than a positive margin, would you offer APBI in an attempt to reduce cardiac dose?
Would you recommend PMRT in a patient with a triple negative cT2N0, ypT2N0 metaplastic breast cancer s/p NAC, mastectomy, and SLNB?
When should the dissected axilla (levels I-II) be included when delivering RNI?
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?
Do you hold endocrine therapy during adjuvant breast radiotherapy?
How do you approach boost to the lumpectomy cavity AND 4 lymph nodes with extra-nodal extension when treating breast cancer with hypofractionation?
Have the breast surgeons at your institution adopted the SOUND trial into their clinical practice?
Is it reasonable to extrapolate the findings of RT Charm and Alliance to intact breast patients and offer hypofractionated RNI to all patients who are eligible for RNI?
Is there any increased risk with adjuvant breast radiation for a patient with muscular dystrophy?
Do you recommend adjuvant RT to patients with non-ATM genetic mutations (e.g. BRCA, NF) who elect to have lumpectomy and are otherwise PRIME II/CALGB candidates for RT omission (i.e. low risk disease characteristics: strongly ER+, <1cm, grade 1-2, no LVI, widely negative margins, and committed to endocrine therapy)?